tbuckley/cabot-search huggingface dataset:
P104Long-term results of percutaneous coronary interventions in comparison with drug therapy in patients with stable angina pectoris
Authors: E Samoilova, V A Kuznetsov
Journal: Cardiovascular Research (2018)

were used.Washed RBCs from WT or db/db mice treated with vehicle or nitrate were administered to WT hearts at the onset of ischemia.In both protocols post-ischemic recovery of cardiac function was evaluated by determination of left ventricular developed pressure (LVDP).Results: Post-ischemic recovery of LVDP was impaired in hearts from db/db mice in comparison with hearts from WT mice in Protocol 1 (Fig. A).Dietary nitrate restored the ischemic tolerance of hearts from db/db mice but did not affect post-ischemic recovery of hearts from WT mice (Fig. A).In Protocol 2, administration of RBCs collected from vehicle-treated db/db mice significantly impaired post-ischemic recovery of hearts from WT mice (Fig. B).Notably, administration of RBCs from nitrate-treated db/db mice completely reversed the impairment of post-ischemic cardiac function induced by diabetic RBCs (Fig. B).Interestingly, post-ischemic cardiac function did not differ between hearts given RBCs from nitrate-treated db/db and WT mice (Fig. B).Conclusion: Dietary nitrate restores cardiac ischemic tolerance in db/db mice and protects the heart against ischemia-reperfusion injury via an effect mediated through RBCs.
Impact of sustained virological response in the use of concomitant drugs in hepatitis C virus infected patients with comorbidities
Authors: E. González-Colominas, M. Batlle, Inés Monge-Escartín, M. Puigvehí, T. Broquetas, N. Cañete, M.G. Retortillo, S. Coll, R.S. Lamoglia, S.G. Cerrato, J.A. Carrión
Journal: Journal of Hepatology (2018)
Hepatitis B splice variants are strongly associated with and are indeed predictive of hepatocellular carcinoma
Authors: M.-H. Pan, H.-H. Hu, H. Mason, J. Bayliss, M. Littlejohn, Y.-L. Lin, C.-Y. Su, C.-T. Chiang, C.-J. Chen, S. Locarnini, H.-I. Yang, P. Revill
Journal: Journal of Hepatology (2018)
Peginterferon is superior to nucleos(t)ide analogues for reduction ofchronic hepatitis B-related hepatocellular carcinoma in patients with high-riskscore
Authors: P. Ren, Z. Cao, R. Mo, Y. Liu, C. Lichang, Z. Tianhui, Z. LI, J. Lu, Y. Liu, Q. Guo, R. Chen, H. Zhou, W. Cai, H. Wang, H. Gui, Q. Xie
Journal: Journal of Hepatology (2018)
Self-stabilized chitosan and its complexes with carboxymethyl starch as excipients in drug delivery
Authors: Mihaela Leonida, Pompilia Ispas-Szabo, Mircea Alexandru Mateescu
Journal: Bioactive Materials (2018)

This study focuses on the behavior of chitosan (CHI) and its polyelectrolyte complexes with carboxymethyl starch (CMS) used as monolithic matrices with acetaminophen as drug tracer. Two different chitosan grades were tested alone or associated in various ratios with CMS as excipients for tablets obtained by direct compression. The degree of deacetylation (DDA) of CHI, estimated from 1H NMR and FTIR data, was correlated with X-ray diffraction and scanning electron microscopy (SEM) to evaluate structural organization of the monolithic matrices. In vitro drug dissolution assays showed major differences in CHI kinetic profiles between tablets exposed to acidic medium for 2h (to mimick gastric passage) prior to dissolution in simulated intestinal fluid (SIF), and those administered directly to SIF. Prior exposure to acidic SGF conducted to longer dissolution profiles (release completed after 16 h) and preservation of tablet shape, whereas tablets directly incubated in SIF were rapidly disintegrated. The improved properties of chitosan matrices exposed to SGF may be related to an outer compact coating layer (visible in SEM). The effect of self-stabilization of chitosan in acidic medium was compared to that due to formation of polyelectrolyte complexes (PEC) in co-processed polymeric systems (CHI:CMS). The self-formed membrane following exposure to gastric acidity appears to help maintaining tablet integrity and allows higher drug loading, recommending CHI and its complexes with CMS as excipients for drug delivery.
No evidence of fibrosis regression in HCV/HIV co-infected and HCV monoinfected participants up to 3 years after achieving SVR with DAA treatment: Interim results for the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)
Authors: M. Peters, M. Kang, R. Murphy, R. Matining, W. Rosenberg, D. Wyles
Journal: Journal of Hepatology (2018)
Long Noncoding RNA AB074169 Inhibits Cell Proliferation via Modulation of KHSRP-Mediated CDKN1a Expression in Papillary Thyroid Carcinoma
Authors: Qiheng Gou, Linbo Gao, Xinwen Nie, Wenchen Pu, Jingqiang Zhu, Yichao Wang, Xuesha Liu, Shuangyan Tan, Jian-Kang Zhou, Yanqiu Gong, Juan He, Ke Wu, Yuxin Xie, Wanjun Zhao, Lunzhi Dai, Lunxu Liu, Rong Xiang, Yu-Quan Wei, Lin Zhang, Yong Peng
Journal: Cancer Research (2018)

Abstract Long noncoding RNAs (lncRNA) are emerging as a novel class of regulators in gene expression associated with tumorigenesis. However, the role of lncRNAs in papillary thyroid carcinoma (PTC) is poorly understood. Here, we conducted global lncRNA profiling and identified lncRNA AB074169 (lncAB) as significantly downregulated in PTC. Decreased expression of lncAB in PTC was caused by CpG hypermethylation within its gene promoter. Functional studies showed that lncAB overexpression led to cell-cycle arrest and tumor growth inhibition in vitro and in vivo, whereas lncAB knockdown promoted cell proliferation. Mechanistic analyses revealed that lncAB bound KH-type splicing regulatory protein (KHSRP) and also decreased expression of KHSRP, thus increasing CDKN1a (p21) expression and decreasing CDK2 expression to repress cell proliferation. Taken together, these findings demonstrate that lncAB functions as a tumor suppressor during PTC tumorigenesis. Significance: These findings identify a tumor-suppressive long noncoding RNA in papillary thyroid carcinoma. Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/15/4163/F1.large.jpg. Cancer Res; 78(15); 4163–74. ©2018 AACR.
Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy
Authors: Daniel L. Hertz, Kelley M. Kidwell, Kiran Vangipuram, Feng Li, Manjunath P. Pai, Monika Burness, Jennifer J. Griggs, Anne F. Schott, Catherine Van Poznak, Daniel F. Hayes, Ellen M. Lavoie Smith, N. Lynn Henry
Journal: Clinical Cancer Research (2018)

Abstract Purpose: Paclitaxel exposure, specifically the maximum concentration (Cmax) and amount of time the concentration remains above 0.05 μmol/L (Tc&amp;gt;0.05), has been associated with the occurrence of paclitaxel-induced peripheral neuropathy. The objective of this study was to validate the relationship between paclitaxel exposure and peripheral neuropathy. Experimental Design: Patients with breast cancer receiving paclitaxel 80 mg/m2 × 12 weekly doses were enrolled in an observational clinical study (NCT02338115). Paclitaxel plasma concentration was measured at the end of and 16–26 hours after the first infusion to estimate Cmax and Tc&amp;gt;0.05. Patient-reported peripheral neuropathy was collected via CIPN20 at each dose, and an 8-item sensory subscale (CIPN8) was used in the primary analysis to test for an association with Tc&amp;gt;0.05. Secondary analyses were conducted using Cmax as an alternative exposure parameter and testing each parameter with a secondary endpoint of the occurrence of peripheral neuropathy–induced treatment disruption. Results: In 60 subjects included in the analysis, the increase in CIPN8 during treatment was associated with baseline CIPN8, cumulative dose, and relative dose intensity (P &amp;lt; 0.05), but neither Tc&amp;gt;0.05 (P = 0.27) nor Cmax (P = 0.99). In analyses of the secondary endpoint, cumulative dose (OR = 1.46; 95% confidence interval (CI), 1.18–1.80; P = 0.0008) and Tc&amp;gt;0.05 (OR = 1.79; 95% CI, 1.06–3.01; P = 0.029) or Cmax (OR = 2.74; 95% CI, 1.45–5.20; P = 0.002) were associated with peripheral neuropathy–induced treatment disruption. Conclusions: Paclitaxel exposure is predictive of the occurrence of treatment-limiting peripheral neuropathy in patients receiving weekly paclitaxel for breast cancer. Studies are warranted to determine whether exposure-guided dosing enhances treatment effectiveness and/or prevents peripheral neuropathy in these patients. Clin Cancer Res; 24(15); 3602–10. ©2018 AACR.
Left Ventricular Longitudinal Strain and Strain Rate Values According to Sex and Classifications of Sports in the Young University Athletes Who Participated in the 2015 Gwangju Summer Universiade
Authors: Jae-Hyeong Park, Jin Kyung Oh, Kye Hun Kim, Jae Yeong Cho, Goo-Yeong Cho, Jae-Hwan Lee, In-Whan Seong, Lawrence Rink, Kyle Hornsby, Myung Ho Jeong, Jeong Gwan Cho, Jong Chun Park
Journal: JACC. Cardiovascular imaging (2018)
Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in <i>KRAS</i> Wild-Type Metastatic Colorectal Cancer
Authors: Amanda Townsend, Niall Tebbutt, Christos Karapetis, Pamela Cooper, Nimit Singhal, Susan Yeend, Louise Pirc, Rohit Joshi, Jennifer Hardingham, Timothy Price
Journal: Clinical Cancer Research (2018)

Purpose: Inhibition of mTOR in addition to EGFR may overcome resistance to EGFR inhibitors in metastatic colorectal cancer (mCRC). This phase Ib/II study evaluated the safety and efficacy of the combination of irinotecan, panitumumab, and everolimus.Patients and Methods: Patients with KRAS exon 2 wild-type (WT) mCRC following failure of fluoropyrimidine-based therapy received i.v. irinotecan and panitumumab every 2 weeks, and everolimus orally throughout a 14-day cycle. The primary endpoint of the phase II study was response rate (RR). Secondary survival outcomes were calculated using the Kaplan-Meier method, and results were analyzed as intention to treat. A preplanned exploratory biomarker analysis was performed.Results: Forty-nine patients were enrolled. Dose level 1 (irinotecan 200 mg/m2, panitumumab 6 mg/kg, and everolimus 5 mg alternate day) was declared the MTD with no dose-limiting toxicities in six patients. Forty patients were treated at dose level 1: median age, 60 years (37-76); 65% male; 45% and 52.5%, respectively, with Eastern Cooperative Oncology Group values of 0/1. Median dose intensity was 85%. Grade 3 toxicities were diarrhea (23%), mucositis (18%), rash (13%), fatigue (8%), dehydration (5%), neutropenia (20%), febrile neutropenia (8%), hypomagnesemia (20%), and hypokalemia (8%). Grade 4 toxicities were hypomagnesemia (5%) and neutropenia (3%). RR was 48%, and stable disease was 43%. Median progression-free survival (PFS) was 5.6 months, and median overall survival (OS) was 10.8 months. Twenty-five patients were RAS/RAF WT and had an RR of 60%, median PFS of 6.4 months, and OS of 11.8 months.Conclusions: The toxicity of the panitumumab, irinotecan, and everolimus regimen is as expected and manageable. The RR of 60% in all RAS/RAF WT supports further study of this combination. Clin Cancer Res; 24(16); 3838-44. ©2018 AACR.
Better care for patients with cancer
Authors: Fiona Godlee
Journal: BMJ (2018)

For many people, cancer is now survivable and has become a long term condition. This week our clinical update reminds us to think about the psychological impact for the growing number of people living with cancer (doi:10.1136/bmj.k1415). As Alexandra Pitman and colleagues explain, depression and anxiety are more common in cancer survivors than in the general population and can occur at all stages of the cancer journey, whether as part of the initial presentation or after a patient is discharged from active management, when the intense schedule of tests …
CCL21 as a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis
Authors: Anna‐Maria Hoffmann‐Vold, Roger Hesselstrand, Håvard Fretheim, Thor Ueland, Arne K. Andreassen, Cathrine Brunborg, Vyacheslav Palchevskiy, Øyvind Midtvedt, Torhild Garen, Pål Aukrust, John A. Belperio, Øyvind Molberg
Journal: Arthritis & Rheumatology (2018)

Systemic sclerosis (SSc) is a major cause of pulmonary arterial hypertension (PAH). Murine models indicate key roles for chemokines CCL19 and CCL21 and their receptor CCR7 in lung inflammation leading to PAH. The objective of this study was to assess the chemokine CCL19-CCL21 axis in patients with SSc-related PAH.Serum samples obtained from 2 independent prospective SSc cohorts (n = 326), patients with idiopathic PAH (n = 12), and healthy control subjects (n = 100) were analyzed for CCL19/CCL21 levels, by enzyme-linked immunosorbent assay. The levels were defined as either high or low, using the mean + 2 SD value in controls as the cutoff value. Risk stratification at the time of PAH diagnosis and PAH-related events were performed. Descriptive and Cox regression analyses were conducted.CCL21 levels were higher in patients with SSc compared with controls and were elevated prior to the diagnosis of PAH. PAH was more frequent in patients with high CCL21 levels (≥0.4 ng/ml) than in those with low CCL21 levels (33.3% versus 5.3% [P < 0.001]). In multivariate analyses, CCL21 was associated with PAH (hazard ratio [HR] 5.1, 95% CI 2.39-10.76 [P < 0.001]) and occurrence of PAH-related events (HR 4.7, 95% CI 2.12-10.46, P < 0.001). Risk stratification at the time of PAH diagnosis alone did not predict PAH-related events. However, when risk at diagnosis was combined with high or low CCL21 level, there was a significant predictive effect (HR 1.3, 95% CI 1.03-1.60 [P = 0.027]). A high CCL21 level was associated with decreased survival (P < 0.001).CCL21 appears to be a promising marker for predicting the risk of SSc-related PAH and PAH progression. CCL21 may be part of a dysregulated immune pathway linked to the development of lung vascular damage in SSc.
Real-life effectiveness and safety of Glecaprevir/Pibrentasvir among 723 Italian patients with chronic hepatitis C: The Navigator-II study
Authors: R. D’Ambrosio, L. Pasulo, M. Puoti, M. Schiavini, P. Viganò, M. Vinci, B. Menzaghi, M.G. Zuin, A. Soria, A. Spinetti, A. Aghemo, M.G. Rumi, C. Uberti-Foppa, A. Pan, O. Spinelli, A. D’arminio Monforte, A. Capretti, A. Colli, A. Colombo, G. Spinzi, R. Centenaro, E. Buscarini, R. Soffredini, M. Borghi, M. Colpani, S. Lazzaroni, F. Maggiolo, A. Gori, P. Del Poggio, A. Giorgini, L. Morini, M.G. Pigozzi, C. Dibenedetto, O. Giglio, C.F. Magni, F. Noventa, P. Lampertico, S. Fagiuoli
Journal: Journal of Hepatology (2018)
Familiality of Psychiatric Disorders and Risk of Postpartum Psychiatric Episodes: A Population-Based Cohort Study
Authors: Anna E. Bauer, Merete L. Maegbaek, Xiaoqin Liu, Naomi R. Wray, Patrick F. Sullivan, William C. Miller, Samantha Meltzer-Brody, Trine Munk-Olsen
Journal: American Journal of Psychiatry (2018)

Postpartum psychiatric disorders are common and morbid complications of pregnancy. The authors sought to evaluate how family history of psychiatric disorders is associated with postpartum psychiatric disorders in proband mothers with and without a prior psychiatric history by assessing degree of relationship, type of disorder, and sex of family members.The authors linked Danish birth and psychiatric treatment registers to evaluate familial risk of postpartum psychiatric episodes in a national population-based cohort. Probands were first-time mothers who were born in Denmark in 1970 or later and who gave birth after age 15 and before Dec. 31, 2012 (N=362,462). The primary exposure was a diagnosed psychiatric disorder in a relative. Cox regression models were used to estimate the hazard ratio of postpartum psychiatric disorders in proband mothers.The relative risk of psychiatric disorders in the postpartum period was elevated when first-degree family members had a psychiatric disorder (hazard ratio=1.45, 95% CI=1.28-1.65) and highest when proband mothers had a first-degree family member with bipolar disorder (hazard ratio=2.86, 95% CI=1.88-4.35). Associations were stronger among proband mothers with no previous psychiatric history. There were no notable differences by sex of the family member.Family history of psychiatric disorders, especially bipolar disorder, is an important risk factor for postpartum psychiatric disorders. To assist in identification of women at risk for postpartum psychiatric disorders, questions related to female and male first-degree relatives with bipolar disorder are of the highest importance and should be added to routine clinical screening guidelines to improve prediction of risk.
Association of nonalcoholic fatty liver disease with changes in left ventricular structure and function: The coronary artery risk development in young adults (CARDIA) study
Authors: L. Vanwagner, H. Ning, J. Wilcox, C. Lewis, J. Lima, J.J. Carr, M. Rinella, S. Shah, D. Lloyd-Jones
Journal: Journal of Hepatology (2018)
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study
Authors: Luana Calabrò, Aldo Morra, Diana Giannarelli, Giovanni Amato, Armida D'Incecco, Alessia Covre, Arthur Lewis, Marlon C Rebelatto, Riccardo Danielli, Maresa Altomonte, Anna Maria Di Giacomo, Michele Maio
Journal: The Lancet Respiratory Medicine (2018)
Abstract 13949: Biomarkers for Prediction of Atrial Fibrillation in European Cohorts
Authors: Renate B Schnabel, Teemu Niiranen, Francesco Gianfagna, Julie K Vishram, Francisco M Ojeda, Simona Costanzo, Stefan Soederberg, Erkki Vartiainen, Maria Benedetta Donati, Gerard Pasterkamp, Maria Hughes, Jukka Kontto, Martin Bobak, Arne Schillert, Hester M den Ruijter, Ellisiv Mathiesen, Wolfgang König, Wolfgang König, Wolfgang König, Stefan Blankenberg, Giovanni de Gaetano, Torben Joergensen, Kari Kuulasmaa, Veikko Salomaa, Licia Iacoviello, Tanja Zeller
Journal: Circulation (2016)

Introduction: Blood-based biomarkers are objective tools to assess susceptibility for atrial fibrillation (AF). Hypothesis: Whether novel biomarkers improve risk prediction based on clinical risk factors and N-terminal pro B-type natriuretic peptide (Nt-proBNP) remains to be shown. Methods: In individuals from two European community studies (N=32,318) we examined 11 circulating biomarkers representing lipids (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, lipoprotein(a), apolipoprotein A1, apolipoprotein B), inflammation (C-reactive protein), renal function (cystatin C), myocardial damage (high sensitivity assayed troponin I (hsTnI)), and vitamin D in relation to incidence of AF in addition to clinical risk factors and Nt-proBNP. Multivariable-adjusted Cox regression models were computed for models comprising classical cardiovascular risk factors and biomarkers. Net reclassification improvement (NRI) was computed. Results: The median age was 53.2 (interquartile range 44.0, 62.9) years, age range 24.1-97.6 years, 51.9% women. Over a median follow-up of 4.9 years N=893 AF cases occurred. In multivariable-adjusted models there was evidence for an association between one standard deviation increase in biomarker for total cholesterol (hazard ratio (HR) 0.90, 95% confidence interval (CI) 0.83-0.97;P=0.0042), LDL cholesterol (HR 0.89, 95% CI 0.82-0.96; P=0.0015), apolipoprotein B (HR 0.89, 95% CI 0.83-0.96; P=0.0033), cystatin C 1/3 (HR 1.19, 95% CI 1.11-1.28; P&lt;0.001), hsTnI 1/3 (HR 1.09, 95% CI 1.04-1.13;P&lt;0.001), besides Nt-proBNP (HR 1.99, 95% CI 1.86-2.13;P&lt;0.001). Only Nt-proBNP increased the C-index markedly to 0.872 (95% CI 0.844-0.901) compared to the model based on clinical risk factors C-index 0.836 (95% CI 0.809-0.863). Similarly, only Nt-proBNP improved reclassification (NRI 0.219, 95% CI 0.159-0.279). Conclusions: Several known and novel biomarkers including blood lipids (total and LDL cholesterol, lipoprotein B), hsTnI and cystatin C are related to incident AF in large European cohorts. None proved to be superior to Nt-proBNP in C-statistic and net reclassification analyses. A possible benefit in the clinical application of Nt-proBNP for AF risk prediction needs to be shown.
Erratum. Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. Diabetes Care 2016;39:808–815
Authors: Sarah Steven, Kieren G. Hollingsworth, Ahmad Al-Mrabeh, Leah Avery, Benjamin Aribisala, Muriel Caslake, Roy Taylor
Journal: Diabetes Care (2018)

An error has been identified in the formula used to calculate VLDL1 production rate in the article cited above. This error does not affect the conclusions of the study …
Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use
Authors: E. Gane, W.-K. Seto, H. Janssen, F.A. Caruntu, H.J. Kim, D. Abdurakhmanov, S. Nishiguchi, H. Andrzej, H. Bae, S. Mo, V. Suri, A. Gaggar, J.F. Flaherty, J.-H. Kao, M. Brunetto, M.B. Ferret
Journal: Journal of Hepatology (2018)
When You Hear Hoofbeats, Look for Horses, Not Zebras—Reply
Authors: Yin P. Hung, Lucian R. Chirieac
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal